CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $278,000 | -69.8% | 3,826 | -53.6% | 0.03% | -66.7% |
| Q3 2021 | $922,000 | -28.8% | 8,239 | +3.0% | 0.09% | -30.8% |
| Q2 2021 | $1,295,000 | +37.3% | 8,002 | -1.8% | 0.13% | +19.3% |
| Q1 2021 | $943,000 | -8.3% | 8,145 | +32.7% | 0.11% | -12.8% |
| Q4 2020 | $1,028,000 | +68.8% | 6,138 | +4.2% | 0.12% | +13.6% |
| Q3 2020 | $609,000 | +46.4% | 5,890 | +11.1% | 0.11% | +23.6% |
| Q2 2020 | $416,000 | +49.6% | 5,300 | +2.9% | 0.09% | +34.8% |
| Q1 2020 | $278,000 | +62.6% | 5,150 | +51.5% | 0.07% | +73.7% |
| Q3 2019 | $171,000 | +31.5% | 3,400 | +28.3% | 0.04% | +26.7% |
| Q2 2019 | $130,000 | – | 2,650 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |